PALM DESERT, CA / ACCESSWIRE / November 5, 2019 / Full Alliance Group, Inc. (OTCPINK:FAGI) ('Full Alliance Group' or the 'Company') medical team of Dr Louie Yu and Dr Leonid Macherete recently returned from Trinidad and Thailand, respectively, after successful clinical engagements. In addition, Dr Matt Cook, CMO of FAGI and recipient of one of the first portable EBO2 devices, has far exceeded volume projections at FAGI's national training center.

Paul Brian Volpp, MD, MPH, CEO and President of Full Alliance Group, commented, 'We are grateful for the time that our medical advisory board has taken to start spreading the word about the benefits of ozone and orthomolecular medicine'.

Dr Yu and his team returned from a week of training staff and treating patients with the portable EBO2 at the new Hadassah medical school in Trinidad. As a result Dr Yu has been asked to spearhead the orthomolecular medicine curriculum when the school formally opens its doors in 2020.

In addition, Dr Macherete was guest speaker for the A4P Conference in Bangkok, Thailand. He plans to return early next year together with Dr Yu to further teach Asian practitioners of the benefits of the Yu Method.

Sincerely,

Paul Brian Volpp, MD, MPH,
President / CEO
The Full Alliance Group

About Full Alliance Group Inc.

Full Alliance Group Inc. (OTCPK: FAGI) is a multi-faceted holding company with various interests in technology, healthcare, and nutraceuticals. Nutra Yu, Inc., a wholly owned subsidiary of Full Alliance Group, develops, markets, and distributes a proprietary line of nutraceutical products. EBO2, Inc., a wholly owned subsidiary of Full Alliance Group, is the provider of ''EBO2'', is a modern high volume blood gas exchange unit for the treatment of 5-7 liters of blood with medical ozone, the unit allows extracorporeal blood and oxygenation and ozone exposure and blood filtration via the filter in a unique way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins which are in excess in the venous blood supply. The EBO2 unit is considered the world's most advanced medical ozone therapy performed today.

For additional information regarding Full Alliance Group, visit, www.fullalliance.com.

Full Alliance Group Inc. Investor Relations

Dave Donlin
Email: Info@TheCervelleGroup.com
Phone: (407) 490-6635
Web: www.StockInvestorDaily.com
Visit: www.fullalliance.com
Contact: ir@fullalliance.com

Forward-Looking Statements

This shareholder update may contain a number of forward-looking statements. Words and variations of words such as: 'expect', 'goals', 'could', 'plans', 'believe', 'continue', 'may', 'will', and similar expressions are intended to identify our forward-looking statements, including but not limited to: our expectation for growth, benefits from brand-building, cost savings and margins. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Such factors include, but are not limited to: continued volatility of, and sharp increase in: costs/pricing actions, increased competition, ability to raise sufficient operating capital, risks from operating internationally, consumer weakness, weakness in economic conditions and tax law changes.

SOURCE: Full Alliance Group, Inc.